Sanofi Consumer Healthcare India Ltd (SANOFICONR)
₹4,106.00
Mkt cap
₹9,456 Cr
P/E ratio
35.60
P/B
27.19
Div yield
1.83%
ROE
71.60%
ROCE
89.90%
EPS (TTM)
₹115.34
Book value
₹151
52W range
4,000–5,293
Sector
Healthcare
Price history
Previous close
Incorporated in 2023, Sanofi Consumer Healthcare India Ltd manufactures and trading of drugs & pharmaceutical products. [1] It is a division of Sanofi, a global pharmaceutical company, focusing on over-the-counter (OTC) and consumer healthcare products. [2]
NSE SANOFICONRBSE 544250
Health check
Mixed
ValuationFair
ProfitabilityStrong
GrowthModerate
TechnicalsBearish
52-week range
−22.42% from high₹4,106
₹4,000+2.66% from low₹5,293
Current
₹4,106.00
Prev close
₹4,201.70
Day
−2.28%
Price performance
1D
−2.75%
1W
−1.31%
1M
−9.49%
3M
−13.31%
6M
−3.62%
1Y
−19.72%
YTD
−10.66%
Financials
Revenue, profit & margin
P/E ratio
35.6×
SANOFICONR is 2% above the sector median of 35.1×
SANOFICONR35.6×
Sector median35.1×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 210 | 225 | 222 | 172 | 160 | 171 | 173 | 221 | 234 | 251 | 229 | 236 | |
| Expenses | 116 | 135 | 140 | 109 | 97 | 109 | 109 | 151 | 149 | 161 | 140 | 146 | |
| Operating Profit | 95 | 90 | 82 | 64 | 63 | 62 | 64 | 70 | 85 | 90 | 89 | 89 | |
| OPM % | 45% | 40% | 37% | 37% | 39% | 36% | 37% | 32% | 36% | 36% | 39% | 38% | |
| Other Income | 1 | 1 | 3 | -24 | 3 | 2 | 5 | 12 | 3 | 5 | 6 | 6 | |
| Interest | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | |
| Depreciation | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 3 | 3 | 3 | 3 | |
| Profit before tax | 95 | 90 | 84 | 39 | 61 | 63 | 67 | 79 | 84 | 90 | 91 | 92 | |
| Tax % | 25% | 24% | 25% | 25% | 26% | 29% | 25% | 23% | 25% | 27% | 25% | 25% | |
| Net Profit | 71 | 68 | 63 | 29 | 45 | 44 | 50 | 61 | 63 | 66 | 68 | 69 | |
| EPS in Rs | 12.59 | 19.54 | 19.24 | 21.71 | 26.36 | 27.31 | 28.87 | 29.44 | 29.87 | ||||
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +0.81% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 28 Jul '26◦ |
| Earnings day | +0.81% |
| +1 day | −1.86% |
| +5 days | −3.31% |
| +15 days | −10.31% |
| +30 days | — |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202671.27%Promoter
Promoters71.27%
FIIs2.60%0.16
DIIs17.85%0.28
Public8.28%0.13
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,895.00 | 35.99 | 4,54,674 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,315.00 | 83.00 | 2,47,284 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,914.00 | 83.77 | 1,86,913 | 0.77% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| ZYDUSLIFE | ₹1,156.90 | 23.70 | 1,15,401 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| CIPLA | ₹1,395.00 | 31.49 | 1,12,696 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| LAURUSLABS | ₹1,876.70 | 92.74 | 1,01,400 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,105.00 | 16.17 | 96,254 | 0.86% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| SANOFICONR | ₹4,106.00 | 35.55 | 9,456 | 1.83% | 69 | +23.65% | 236 | +6.70% | 89.93% |
| Median: 159 Co. | ₹423.00 | 35.07 | 2,282 | 0.08% | 13 | +29.60% | 162 | +18.62% | 15.04% |
Filings
Annual reports2
Concall transcripts2
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 30 Jul - Copy of Newspaper Publication of Unaudited Financial Results for the quarter and half year ended 30th June 2026 is enclosed.Announcement under Regulation 30 (LODR)-Press Release / Media Release 28 Jul - Board approved Q2 FY26 results: revenue ₹2,357 million, net profit ₹919 million; H1 revenue ₹4,649 million.Results - Financial Results For June 30, 2026 28 JulBoard Meeting Outcome for Outcome Of Board Meeting Held On Tuesday, 28Th July 2026 28 Jul - Board approved Q2 FY26 results; revenue ₹2,357 million, PBT ₹919 million, H1 revenue ₹4,649 million.Board Meeting Intimation for Board Meeting Intimation For Consideration And Approval Of Unaudited Financial Results For The Quarter And Half Year Ended 30Th June 2026. 22 Jul - Board meeting on 28 July 2026 to approve Q1 and half-year FY2026 unaudited results; trading window closed till 30 July.